Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Sentio BioSciences Expands Maryland Heights, Missouri, Production Operations

06/14/2025
Sentio BioSciences, a vertically integrated pharmaceutical manufacturer, plans to expand its production operations in Maryland Heights, Missouri. The more than $10.6 million project is expected to create 58 jobs.

The investment will include the increase in capacity for the domestic manufacturing of generic medicines, including key starting materials, Active Pharmaceutical Ingredients, and drug products. The expansion is scheduled for completion in 2026.

“Sentio has been a strong advocate for manufacturing essential medicines in the United States, emphasizing high quality, secure and reliable supply,” said Karthik Raghavan, CEO of Sentio BioSciences. “This expansion announcement shows our continued commitment and builds on our successful track record for manufacturing essential medicines domestically.”

To support the project Sentio will benefit from the Missouri Works program, a tool that helps companies expand and retain workers by providing access to capital through withholdings or tax credits for job creation.

“Sentio BioSciences’ expansion speaks to Missouri’s ability to produce and support companies that transform industries and improve lives,” noted Michelle Hataway, Director of the Department of Economic Development. “We’re proud to join our partners in ensuring this local employer, innovator, and job creator continues to help Missourians prosper.”

Sentio BioSciences specializes in the development and manufacturing of both new and generic drugs for human and animal health. The company is a CDMO (Contract Development and Manufacturing Organization) focused on advanced pharmaceutical development, manufacturing, and commercialization.

Exclusive Research